Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial

BACKGROUND: There is no consensus on the therapeutic approach to ECOG 2 patients with locally advanced non-small-cell lung cancer (LA-NSCLC), despite the sizable percentage of these patients in clinical practice. This study focused on the efficacy, toxicity and the optimal chemotherapy regimen of CC...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMC Cancer
Asıl Yazarlar: Bi, Nan, Liu, Lipin, Liang, Jun, Wu, Shixiu, Chen, Ming, Lv, Changxing, Zhao, Lujun, Shi, Anhui, Jiang, Wei, Xu, Yaping, Zhou, Zongmei, Wang, Jingbo, Wang, Wenqing, Chen, Dongfu, Hui, Zhouguang, Lv, Jima, Zhang, Hongxing, Feng, Qinfu, Xiao, Zefen, Wang, Xin, Zhang, Tao, Yin, Weibo, Li, Junling, He, Jie, Wang, Luhua
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2020
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7137304/
https://ncbi.nlm.nih.gov/pubmed/32252680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06780-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller